Osteoporotic fracture significantly increase the morbidity and mortality of affected patients. Many patients are poorly compliant with their treatment because of side effects such as esophageal irritation. Therefore, intravenous bisphosphonate such as Zoledronate (ZA) is preferred in non-compliant patients. postmenopausal women, osteoporosis, zoledronate
Conditions
Interventions
annual infusion of 4 mg of zoledronate over three years.
Experimental Drug
ZA 4 mg
Sponsors
None listed
Eligibility
Sex/Gender
Female
Age
45 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. postmenopausal osteoporotic women from internal medicine and rheumatology outpatient clinic, Phramongkutklao Hospital 2. osteoporosis is defined according to the WHO criteria.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of prior anti-resorptive treatments, such as bisphosphonates, estrogen replacement therapy, calcitonin, and raloxifene 2. patients with moderate to severe renal impairment (glomerular filtration rate < 35 mL/min, estimated by the CKD-EPI equation) 3. Patients with a known allergy to bisphosphonates, 4. Patients planning invasive dental surgery within 12 months after zoledronate infusion 5. Patients with a history of atrial fibrillation 6. Patients with a history of hyperparathyroidism 7. Patients with a history of vitamin D insufficiency 8. Patients with secondary osteoporosis were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone mineral density at 24 and 36 months after the intervention Dual energy x ray absorptiometry | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone turnover markers at 24 and 36 months after the intervention P1NP and B-CTX level | — |
Countries
Thailand
Contacts
Public ContactThunyawarin Arunthanachaikul
Phramongkutklao Hospital
Outcome results
None listed